Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 2-12

  Fainardi, Enrico ^a,b   Rizzo, R ^a   Melchiorri, L ^a   Castellazzi, M ^a   Paolino, E ^a   Tola, M R ^a   Granieri, E ^a   Baricordi, O R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cerebrospinal fluid; Intrathecal synthesis; Multiple sclerosis; sHLA G; sHLA I

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; HLA G ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DYSREGULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SYNTHESIS; RELAPSE; REMISSION;

ADULT; DISEASE PROGRESSION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SPINAL CORD;

EID: 31644440878     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458506ms1241oa     Document Type: Article

References (47)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
2. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol 2004; 25: 132-37.
3. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R et al. Clonal expansion of CD8+ T cells dominate the cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
4. Huseby ES, Liggitt D, Brabb T, Schnabel B, Öhlèn C, Governman J. A pathogenic role for myelin-specific CD8+ T cells in model for multiple sclerosis. J Exp Med 2001; 194: 669-76.
5. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neuritis by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-15.
6. + T cells are correlated to MRI features of tissue destruction in MS. J Neuroimmunol 2003; 142: 141-48.
7. - T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur J Immunol 2000; 30: 3623-33.
8. Madakamutil LT, Maricic I, Sercarz E, Kumar V. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J Immunol 2003; 170: 2985-92.
9. - T cells in an autoimmune disease model. J Clin Invest 2003; 112: 1037-48.
10. + T cell responses in patients with multiple sclerosis. J Clin Invest 2002; 109: 641-49.
11. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, Rajewsky K et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansion in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004; 101: 2428-243.
12. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A et al. Oligoclonal expansion of memory CD8+ cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125: 538-50.
13. Redwine JM, Buchmeier MJ, Evans CE In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol 2001; 159: 1219-24.
14. Hofteberger R, Aboul-Enein F, Brueck W, Lucchinetti C, Rodriguez M, Schmidbauer M et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004; 14: 43-50.
15. Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J et al. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. J Neuroimmunol 1998; 86:123-33.
16. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004; 127: 1917-27.
17. McDonald JC, Adamashvili E. Soluble HLA: a review of literature. Hum Immunol 1998; 59: 387-403.
18. Zavazava N, Kronke M. Soluble HLA class I antigens induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2: 1005-10.
19. Puppo F, Contini P, Ghio M, Brenci S, Scudelletti M, Filaci G et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8 (+) Fas (CD95) (+) T lymphocytes. Int Immunol 2000; 12: 195-203.
20. Spaggiari MG, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F et al. Soluble HLA class I induces NK cell apoptosis upon engagement of killer-activating HLA class I receptors through FASL-Fas interaction. Blood 2002; 100: 4098-107.
21. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 22: 553-55.
22. LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 2003; 62: 273-84.
23. 1, domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 1997; 94: 5249-54.
24. + cells by interacting CD8. J Immunol 2000; 164: 6100-104.
25. + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33: 125-34.
26. Kanai T, Fujii T, Kozuma S, Yamashita T, Miki A, Kikuchi A et al. Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture. Mol Hum Reprod 2001; 7: 195-200.
27. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B et al. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol 2002; 32: 311-15.
28. Moreau P, Cabestre FA, Menier C, Gauiard U, Gourand L, Dausset J et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 5: 803-11.
29. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168: 4772-80.
30. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neural 2000; 48: 679-84.
31. Alvarez-Cermeño JC, Villar LM, Nocito M, Bootello A, Gonzales-Porque P. Intrathecal synthesis of soluble HLA class I antigens in multiple sclerosis. J Neuroimmunol 1992; 36: 77-79.
32. Filaci G, Contini P, Bronci S, Gazzola P, Lanza L, Scudeletti M et al. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum Immunol 1997; 54: 54-62.
33. Ott M, Seidl C, Westhoff U, Stecker K, Seifred E, Fischer PA et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens 1998; 51: 301-304.
34. Fainardi E, Granieri E, Tola MR, Melchiorri L, Vaghi L, Rizzo R et al. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA-class I molecules. J Neuroimmunol 2002; 133: 151-59.
35. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L et al. Beneficial effect of interferon-β 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. J Neuroimmunol 2004; 148: 206-11.
36. Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol 2003; 142: 149-58.
37. Poser CM, Paty DW, Scheimberger L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for MS: guidelines for research protocols. Ann Neural 1983; 13: 227-31.
38. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neural 2001; 50: 121-27.
39. Lublin DF, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
40. Kurtzke JE Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 1983; 33: 1444-52.
41. Salden HJM, Bas BM, Hermas JT, Janson PC. Analytical performance of the three commercially available nephelometers compared quantifying protein in serum and cerebrospinal fluid. Clin Chem 1988; 34: 1594-96.
42. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference value. Scand J Clin Lab Invest 1977; 37: 385-90.
43. Inostroza J, Munoz P, Espinoza R, Millaqueo L, Diaz P, Leiva L et al. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tuberculosis. Hum Immunol 1994; 40: 179-84.
44. Mitsdoerffer M, Schreiner B, Kieseier B, Neuhaus O, Dichgans J, Hartung H-P et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005; 159: 155-64.
45. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-78.
46. Ober C, Aldrich C, Rosinsky B, Roberton A, Walker MA, Willadsen S et al. HLA-G1 protein expression is not essential for fetal survival. Placenta 1998; 19: 127-32.
47. Wiendl H, Mitsdoerffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 2003; 13: 343-51.